Replacing universal anti-neuronal antibody screening with clinical assessment and testing of high probability cases in psychotic disorders

Abstract

Get full access to this article

View all access options for this article.

References

Ariño

Coutinho

Pollak

, et al. (2021) Real-world experience of assessing antibodies against the N-methyl-D-aspartate receptor (NMDAR-IgG) in psychiatric patients. A retrospective single-centre study. Brain, Behavior, and Immunity 98: 330–336.

Cahalan

(2012) Brain on Fire: My Month of Madness. New York: Simon and Schuster.

Chan

O’Gorman

Swayne

, et al. (2021) Voltage-gated potassium channel blanket testing in first-episode psychosis: Diagnostic nihilism? Australian and New Zealand Journal of Psychiatry 55: 817–823.

Dalmau

Armangué

Planagumà

, et al. (2019) An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: Mechanisms and models. The Lancet Neurology 18: 1045–1057.

Galletly

Castle

Dark

, et al. (2016) Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Australian and New Zealand Journal of Psychiatry 50: 410–472.

Jeppesen

Nilsson

Sørensen

, et al. (2023) Antineuronal antibodies in cerebrospinal fluid and serum of 104 patients with psychotic disorders compared to 104 individually matched healthy controls. Schizophrenia Research 252: 39–45.

Scott

Gillis

Ryan

, et al. (2018) The prevalence and treatment outcomes of antineuronal antibody-positive patients admitted with first episode of psychosis. BJPsych Open 4: 69–74.

Warren

Flavell

O’Gorman

, et al. (2020) Screening for anti-NMDAR encephalitis in psychiatry. Journal of Psychiatric Research 125: 28–32.

Warren

Freier

Siskind

, et al. (2023) Anti-glutamic acid decarboxylase antibody screening in first-episode psychosis. Australian and New Zealand Journal of Psychiatry 57: 603–612.